PhaseV
PrivateLast Round
Series A
May 13, 2025
Total Funding Raised
$65M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
PhaseV operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A round in May 2025.
PhaseV is a healthcare technology company that provides an AI and machine learning-driven platform to optimize clinical development for biopharma sponsors and contract research organizations.
Sector
Healthcare & Life Sciences
Verticals
Clinical Trials, Healthcare Analytics, Medical AI, Biotechnology
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PhaseV Comparables
Compare PhaseV with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| QuantHealth | 85% | |
| Intelligencia AI | 83% | |
| Phesi | 83% |
For institutional investors. Book with your work email.
PhaseV Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | May 13, 2025 | ||||
| Seed | Oct 24, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
PhaseV Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Viola Ventures | Series A, Seed |
| Exor | Series A |
| LionBird | Series A, Seed |
| Exor Ventures | Series A, Seed |
| Insight Partners | Series A |
| Accel | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 333% to 7.1K.
- Jul 23, 2026
Grew 18% QoQ, from 56 to 66 employees.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- launchesNov 3, 2026
Phasevtrials launches BonV, an agentic product layer that turns clinical development questions into documented, evidence-backed trial decisions, in Massachusetts on Nov 3rd '26.
- hiresSep 16, 2026
Phasevtrials appoints Avi Kulkarni, CEO of InoRx, to its Scientific Advisory Board in Massachusetts on Sep 16th '26 to help guide the expansion of AI Conductor.
- hiresSep 16, 2026
Phasevtrials appoints Klaus Beck, former Chief Medical Officer of Organon, to its Scientific Advisory Board in Massachusetts on Sep 16th '26 to help guide the expansion of AI Conductor.
For institutional investors. Book with your work email.
PhaseV Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about PhaseV's valuation, stock price, and market status.
Is PhaseV a public or private company?
PhaseV is a private company.
What is the current stock price of PhaseV?
PhaseV is a private company, so its shares have no public market price. Caplight tracks PhaseV's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PhaseV worth (valuation)?
Valuation information for PhaseV is not publicly available.
Can I buy PhaseV stock?
PhaseV shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PhaseV's last funding round?
PhaseV's most recent funding round was Series A on May 13, 2025.
Who are the main investors in PhaseV?
Key investors in PhaseV include Viola Ventures, Exor Ventures, Insight Partners, Accel.
Will PhaseV IPO soon?
No public IPO plans have been announced for PhaseV.
How can I track PhaseV secondary market activity?
Caplight tracks bids, offers, and trades in PhaseV's shares on secondary markets.